A Phase 3 interventional study of Herpes Zoster vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 178 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 22 in phase 3, and was the 7th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 1 started in 2012.
This study's enrollment of 1,877 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 9th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2012, is one of 25 in phase 3, and was the 13th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in reducing the risk of developing HZ in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study entry (enrollment) occurs at the Pre-vaccination visit.
OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate for 30 days prior to vaccination with the study vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 12 months after completion of the vaccination series (i.e., until Month 13).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
Biological: Herpes Zoster vaccine GSK1437173A
Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
Biological: Placebo
2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
2 doses administered IM in deltoid region of non-dominant arm
Number of Subjects With Confirmed Herpes Zoster (HZ) Episode
A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings\* suggestive of VZV infection in the absence of characteristic HZ or VZV rash. A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
Time frame: From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Duration of 'Worst' HZ-associated Pain
Duration of HZ-associated pain rated as 3 or greater on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) question, following the onset of a confirmed HZ rash over the entire pain reporting period in subjects with confirmed HZ; presented as T (day) \[=the sum of follow-up period (for subjects without severe worst pain T is 1, for subjects with severe worst pain T is the duration of severe worst pain) expressed in days\].
Time frame: From Month 0 until study end (4 years approximately), from the onset of a confirmed HZ rash over the entire pain reporting period
Number of Subjects With Confirmed HZ-associated Complications
This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Time frame: From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Number of Subjects With Postherpetic Neuralgia (PHN)
This analysis excluded PHN episodes that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Time frame: From Month 0 until study end (21 months median follow-up)
Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects
Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU/mL.
Time frame: At Months 0, 1, 2, 13 and 25
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary/tympanic temperature equal to or above 37.5 degrees Celsius (°C) or rectal temperature equal to or above 38.0 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From Month 0 up to 365 days post last vaccination
Number of Subjects With Any Relapse
Relapse was defined as the occurrence of the underlying malignancy or disease for which the HCT was undertaken.
Time frame: From Month 0 until study end (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Number of Subjects With Any Serious Adverse Events (SAEs) and Related SAEs to GSK Study Vaccine/Placebo
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This enpoint also presents SAES related to the GSK study vaccine/placebo.
Time frame: From Month 0 until 365 days post last vaccination (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Number of Subjects With Fatal SAEs and SAEs Related to Study Participation or to a GSK Concomitant Medication or Vaccination
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This endpoint presents fatal SAEs and SAEs related to study participation or to a concurrent GSK medication/vaccine.
Time frame: From the Pre-vaccination visit (Up to 110 days prior Month 0) until study end (approximate median of 29 months follow-up minimum 1 year and maximum 4 years)
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 922 | 924 |
| Completed | 807 | 795 |
| Not completed | 115 | 129 |
| Withdrew: Serious adverse event | 65 | 67 |
| Withdrew: Adverse event | 14 | 14 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 23 | 30 |
| Withdrew: Migrated/moved from study area | 2 | 4 |
| Withdrew: Lost to follow-up | 4 | 6 |
| Withdrew: Suspected hz episode | 1 | 3 |
| Withdrew: Other reasons for withdrawal | 3 | 4 |
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 922 | 924 |
| Completed | 857 | 854 |
| Not completed | 65 | 70 |
| Withdrew: Serious adverse event | 35 | 38 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Withdrawal by subject | 7 | 8 |
| Withdrew: Migrated/moved from study area | 4 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Lost to follow-up | 5 | 9 |
| Withdrew: Other reasons for withdrawal | 6 | 7 |
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 922 | 924 |
| Completed | 874 | 871 |
| Not completed | 48 | 53 |
| Withdrew: Study end not reached | 48 | 53 |
A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings\* suggestive of VZV infection in the absence of characteristic HZ or VZV rash. A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Confirmed Herpes Zoster (HZ) Episode | 49 | 135 |
Duration of HZ-associated pain rated as 3 or greater on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) question, following the onset of a confirmed HZ rash over the entire pain reporting period in subjects with confirmed HZ; presented as T (day) \[=the sum of follow-up period (for subjects without severe worst pain T is 1, for subjects with severe worst pain T is the duration of severe worst pain) expressed in days\].
| T (day) | GSK1437173A Group | Placebo Group |
|---|---|---|
| Duration of 'Worst' HZ-associated Pain | 892.0 | 6275.0 |
This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Confirmed HZ-associated Complications | 3 | 13 |
This analysis excluded PHN episodes that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Postherpetic Neuralgia (PHN) | 1 | 9 |
Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU/mL.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Anti-gE, Month 0 | 762.8 (568.6 to 1023.5) | 555.0 (404.3 to 761.8) |
| Anti-gE, Month 1 | 1844.2 (1282.2 to 2652.4) | 556.6 (407.3 to 760.6) |
| Anti-gE, Month 2 | 12753.2 (7973.0 to 20399.4) | 443.8 (330.8 to 595.4) |
| Anti-gE, Month 13 | 3183.8 (1869.8 to 5421.2) | 503.6 (307.8 to 824.1) |
| Anti-gE, Month 25 | 2819.0 (1387.1 to 5729.1) | 527.0 (274.3 to 1012.6) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 688 | 56 |
| Grade 3 Pain, Dose 1 | 59 | 3 |
| Any Redness, Dose 1 | 187 | 5 |
| Grade 3 Redness, Dose 1 | 7 | 0 |
| Any Swelling, Dose 1 | 101 | 7 |
| Grade 3 Swelling, Dose 1 | 1 | 0 |
| Any Pain, Dose 2 | 638 | 45 |
| Grade 3 Pain, Dose 2 | 63 | 0 |
| Any Redness, Dose 2 | 231 | 4 |
| Grade 3 Redness, Dose 2 | 24 | 0 |
| Any Swelling, Dose 2 | 132 | 3 |
| Grade 3 Swelling, Dose 2 | 12 | 0 |
| Any Pain, Across doses | 756 | 83 |
| Grade 3 Pain, Across doses | 99 | 3 |
| Any Redness, Across doses | 301 | 9 |
| Grade 3 Redness, Across doses | 28 | 0 |
| Any Swelling, Across doses | 168 | 9 |
| Grade 3 Swelling, Across doses | 13 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary/tympanic temperature equal to or above 37.5 degrees Celsius (°C) or rectal temperature equal to or above 38.0 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Fatigue, Dose 1 | 356 | 282 |
| Grade 3 Fatigue, Dose 1 | 30 | 16 |
| Related Fatigue, Dose 1 | 124 | 55 |
| Any Gastrointestinal, Dose 1 | 150 | 134 |
| Grade 3 Gastrointestinal, Dose 1 | 6 | 7 |
| Related Gastrointestinal, Dose 1 | 41 | 22 |
| Any Headache, Dose 1 | 156 | 121 |
| Grade 3 Headache, Dose 1 | 2 | 3 |
| Related Headache, Dose 1 | 51 | 32 |
| Any Myalgia, Dose 1 | 340 | 170 |
| Grade 3 Myalgia, Dose 1 | 22 | 11 |
| Related Myalgia, Dose 1 | 170 | 50 |
| Any Shivering, Dose 1 | 116 | 73 |
| Grade 3 Shivering, Dose 1 | 6 | 6 |
| Related Shivering, Dose 1 | 56 | 27 |
| Any Temperature, Dose 1 | 60 | 28 |
| Grade 3 Temperature, Dose 1 | 1 | 0 |
| Related Temperature, Dose 1 | 27 | 7 |
| Any Fatigue, Dose 2 | 395 | 212 |
| Grade 3 Fatigue, Dose 2 | 48 | 20 |
| Related Fatigue, Dose 2 | 153 | 41 |
| Any Gastrointestinal, Dose 2 | 142 | 98 |
| Grade 3 Gastrointestinal, Dose 2 | 13 | 12 |
| Related Gastrointestinal, Dose 2 | 51 | 13 |
| Any Headache, Dose 2 | 232 | 88 |
| Grade 3 Headache, Dose 2 | 24 | 8 |
| Related Any Headache, Dose 2 | 95 | 20 |
| Any Myalgia, Dose 2 | 374 | 153 |
| Grade 3 Myalgia, Dose 2 | 42 | 9 |
| Related Myalgia, Dose 2 | 208 | 47 |
| Any Shivering, Dose 2 | 185 | 59 |
| Grade 3 Shivering, Dose 2 | 29 | 1 |
| Related Shivering, Dose 2 | 102 | 16 |
| Any Temperature, Dose 2 | 150 | 28 |
| Grade 3 Temperature, Dose 2 | 2 | 1 |
| Related Temperature, Dose 2 | 8 | 8 |
| Any Fatigue, Across doses | 508 | 340 |
| Grade 3 Fatigue, Across doses | 66 | 31 |
| Related Fatigue, Across doses | 210 | 79 |
| Any Gastrointestinal, Across doses | 238 | 183 |
| Grade 3 Gastrointestinal, Across doses | 18 | 17 |
| Related Gastrointestinal, Across doses | 79 | 30 |
| Any Headache, Across doses | 302 | 166 |
| Grade 3 Headache, Across doses | 26 | 10 |
| Related Headache, Across doses | 123 | 46 |
| Any Myalgia, Across doses | 484 | 234 |
| Grade 3 Myalgia, Across doses | 56 | 19 |
| Related Myalgia, Across doses | 279 | 83 |
| Any Shivering, Across doses | 237 | 115 |
| Grade 3 Shivering, Across doses | 35 | 7 |
| Related Shivering, Across doses | 131 | 38 |
| Any Temperature, Across doses | 183 | 50 |
| Grade 3 Temperature, Across doses | 3 | 1 |
| Related Temperature, Across doses | 101 | 15 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any AE(s) | 360 | 353 |
| Grade 3 AE(s) | 60 | 47 |
| Related AE(s) | 31 | 23 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any pIMDs | 13 | 8 |
| Related pIMDs | 3 | 0 |
Relapse was defined as the occurrence of the underlying malignancy or disease for which the HCT was undertaken.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Relapse | 239 | 253 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This enpoint also presents SAES related to the GSK study vaccine/placebo.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any SAEs, up to Month 13 | 263 | 241 |
| Related SAEs, up to Month 13 | 3 | 4 |
| Any SAEs, up to Study End | 329 | 310 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This endpoint presents fatal SAEs and SAEs related to study participation or to a concurrent GSK medication/vaccine.
| Participants | GSK1437173A Group | Placebo Group | No Group |
|---|---|---|---|
| Fatal SAEs | 118 | 124 | 0 |
| Related SAEs | 37 | 43 | 0 |
Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events (AEs): during the 30-day (Days 0-29) post-vaccination period; SAEs: during the entire study period, up to 365 days post last vaccination (4 years approximately).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 118/922 (12.8%) | 329/922 (35.7%) | 813/922 (88.2%) |
| Placebo Group | 124/924 (13.4%) | 310/924 (33.5%) | 485/924 (52.5%) |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 90/922 | 70/924 |
| PneumoniaInfections and infestations | 55/922 | 41/924 |
| SepsisInfections and infestations | 15/922 | 8/924 |
| Febrile neutropeniaBlood and lymphatic system disorders | 14/922 | 12/924 |
| Diffuse large b-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/922 | 11/924 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/922 | 13/924 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 12/922 | 11/924 |
| Acute kidney injuryRenal and urinary disorders | 12/922 | 4/924 |
| InfluenzaInfections and infestations | 11/922 | 7/924 |
| PyrexiaGeneral disorders | 10/922 | 8/924 |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PainGeneral disorders | 757/922 | 84/924 |
| FatigueGeneral disorders | 509/922 | 341/924 |
| MyalgiaMusculoskeletal and connective tissue disorders | 485/922 | 236/924 |
| ErythemaSkin and subcutaneous tissue disorders | 304/922 | 11/924 |
| HeadacheNervous system disorders | 304/922 | 170/924 |
| ChillsGeneral disorders | 238/922 | 117/924 |
| Gastrointestinal disorderGastrointestinal disorders | 238/922 | 185/924 |
| PyrexiaGeneral disorders | 192/922 | 57/924 |
| SwellingGeneral disorders | 168/922 | 9/924 |
| Age, Continuous(Years) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 54.8 ± 11.7 | 55.1 ± 11.4 | 55.0 ± 11.6 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Female | 342 | 346 | 688 |
| Male | 580 | 578 | 1158 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Geographic ancestry — African Heritage/African American | 15 | 25 | 40 |
| Geographic ancestry — American Indian or Alaskan Native | 2 | 0 | 2 |
| Geographic ancestry — Asian - Central/South Asian Heritage | 6 | 5 | 11 |
| Geographic ancestry — Asian - East Asian Heritage | 83 | 91 | 174 |
| Geographic ancestry — Asian - Japanese Heritage | 43 | 38 | 81 |
| Geographic ancestry — Asian - South East Asian Heritage | 18 | 16 | 34 |
| Geographic ancestry — White - Arabic/North African Heritage | 9 | 12 | 21 |
| Geographic ancestry — White - Caucasian/European Heritage | 715 | 712 | 1427 |
| Geographic ancestry — Mixed Origin | 31 | 25 | 56 |
Showing the first 100 of 178 sites across 28 countries. Choose a country and city above to see the rest.
Ran from Jul 2012 to primary completion in Nov 2016, 51 months.
Results were first posted in Jan 2018, 1 year 2 months after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 51 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix